Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Importance Cardiogenic shock affects between 40 000 and 50 000 people in the US per
year and is the leading cause of in-hospital mortality following acute myocardial infarction …

Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is
increasingly used to treat cardiogenic shock. However, VA-ECMO might hamper myocardial …

Background: Percutaneous mechanical circulatory support devices are increasingly used in
acute myocardial infarction complicated by cardiogenic shock (AMI-CS), despite limited …

Background Single-center studies suggest that implementation of multidisciplinary
cardiogenic shock (CS) teams is associated with improved CS survival. Objectives The aim …

Abstract Background The National Cardiogenic Shock Initiative is a single‐arm, prospective,
multicenter study to assess outcomes associated with early mechanical circulatory support …

Background: Impella was approved for mechanical circulatory support (MCS) in 2008, but
large-scale, real-world data on its use are lacking. Our objective was to describe trends and …

Background: Right ventricular failure (RVF) is a cause of major morbidity and mortality after
left ventricular assist device (LVAD) implantation. It is, therefore, integral to identify patients …

The recent widespread availability and use of mechanical circulatory support is transforming
the management and outcomes of cardiogenic shock (CS). Clinical decision-making …

Abstract Objective The 'Detroit Cardiogenic Shock Initiative'is a single‐arm, multicenter study
to assess the feasibility of early mechanical circulatory support (MCS) in patients who …